Table 2 Odds ratios (ORs) and 95% confidence intervals (CIs) for prenatal exposure to B2AR agonists and AU/ASD in the CHARGE Study (n = 879), California, years 2003 - 2011

Exposure	No. (%)		Adjusted OR (95% CI)[b]	Adjusted OR (95% CI)[c]
	AU/ASD (n=512)	TD (n=367)		
Never[a]			1.00	1.00
Pregnancy period	26 (5.1)	35 (9.5)	0.51 (0.44 - 0.59)	0.53 (0.46 - 0.61)
Never[a]			1.00	1.00
First trimester[d]	14 (2.7)	15 (4.1)	1.10 (0.87 - 1.39)	1.17 (0.94 - 1.47)
Second trimester	21 (4.1)	23 (6.3)	1.21 (1.02 - 1.43)	1.19 (1.01 - 1.40)
Third trimester	20 (3.9)	22 (6.0)	0.48 (0.38 - 0.60)	0.49 (0.40 - 0.61)
None[a]			1.00	1.00
1-2 months[e]	9 (1.8)	21 (5.7)	0.24 (0.21 - 0.29)	0.25 (0.22 - 0.29)
3-9 months	17 (3.3)	14 (3.8)	0.91 (0.69 - 1.20)	0.96 (0.73 - 1.26)

OR odds ratio; *CI* confidence interval; *AU/ASD* autism/autism spectrum disorder; *TD* typical development

[a] Reference group had no exposure to any B2AR agonists during the pregnancy period

[b] Observations were weighted to account for key sociodemographic factors and adjusted for matching variables regional catchment area, child's sex and child's age at enrollment

[c] Observations were weighted and adjusted for the same variables above in addition to maternal birth place

[d] Model simultaneously adjusted for all 3 trimesters. 12 AU/ASD mothers and 9 TD mothers had B2AR agonist exposure during each trimester; 1 AU/ASD mother and 2 TD mothers had B2AR agonist exposure during trimester 1 and 2; 1 TD mother had B2AR agonist exposure during trimester 1 and 3; 4 AU/ASD mothers and 4 TD mothers had B2AR exposure during trimester 2 and 3

[e] Number of different month(s) of B2AR agonist exposure during the pregnancy period